Cellular and Molecular Life Sciences

, Volume 70, Issue 15, pp 2697–2712

Polycystins and cellular Ca2+ signaling

  • D. Mekahli
  • Jan B. Parys
  • G. Bultynck
  • L. Missiaen
  • H. De Smedt
Open Access
Review

Abstract

The cystic phenotype in autosomal dominant polycystic kidney disease is characterized by a profound dysfunction of many cellular signaling patterns, ultimately leading to an increase in both cell proliferation and apoptotic cell death. Disturbance of normal cellular Ca2+ signaling seems to be a primary event and is clearly involved in many pathways that may lead to both types of cellular responses. In this review, we summarize the current knowledge about the molecular and functional interactions between polycystins and multiple components of the cellular Ca2+-signaling machinery. In addition, we discuss the relevant downstream responses of the changed Ca2+ signaling that ultimately lead to increased proliferation and increased apoptosis as observed in many cystic cell types.

Keywords

Calcium signaling Polycystin ADPKD Renal pathology 

Introduction

Autosomal dominant polycystic kidney disease (ADPKD) affects more than 1 in 1,000 live births and is the most common monogenic cause of kidney failure in humans [1, 2, 3, 4]. ADPKD is characterized by the progressive formation and enlargement of renal cysts, typically leading to chronic renal failure by late middle age. In most cases, the disease arises as a consequence of mutations in the PKD1 or PKD2 genes, which encode the proteins polycystin-1 and -2, respectively. Mutations in the PKD1 gene account for approximately 85 % (ADPKD type 1), and mutations in the PKD2 gene account for approximately 15 % (ADPKD type 2) of the affected individuals [2]. Disease progression is typically more rapid in ADPKD type 1, with a mean age of end-stage renal disease approximately 20 years earlier than in type 2, but in all other respects ADPKD types 1 and 2 share almost identical disease phenotypes. This suggests that polycystin-1 and -2 function in common pathways, implying that loss of activity of either protein results in a very similar disease manifestation [5]. The biological role of the polycystin proteins and the molecular basis by which mutational malfunction of either of them leads to cystogenesis, have proven to be very complex, and have been discussed in several recent reviews [1, 2, 6, 7, 8, 9, 10, 11, 12, 13]. A widely accepted view is that polycystin-1 and -2 are functionally associated in a receptor-ion channel complex, in which polycystin-1 acts as a receptor that gates the Ca2+-permeable polycystin-2 channel [14, 15]. Polycystin-1 (4,302 amino acids) contains a large extracellular N-terminal domain, 11 predicted transmembrane spanning segments, and an intracellular C-terminus [16]. The extracellular region of polycystin-1 contains >3,000 amino acids and is implicated in cell–cell and cell–matrix interactions. Polycystin-1 is cleaved at its predicted G-protein-coupled receptor proteolytic site, a feature that could be essential for its biological activity [17]. The intracellular C-terminus of polycystin-1 contains a coiled-coil domain that is involved in the physical interaction with other proteins, and in particular with polycystin-2 [18, 19]. Polycystin-2 is a smaller transmembrane protein (968 amino acids) predicted to have six transmembrane regions and sharing significant homology with transient receptor potential (TRP) channels [9, 12, 13, 20]. Better understanding of the role of the polycystin-1/polycystin-2 complex came from the observation that this co-assembly produced cation-permeable currents at the plasma membrane [21], and participated in mechano-sensation and flow-dependent Ca2+ signaling in the primary cilium [22]. As reviewed recently, there is a clear connection between polycystic kidney disease and dysfunction of ciliary proteins [13]. The precise cellular function of the polycystin proteins is, however, still not completely understood, particularly as both polycystins have been found in cellular locations other than the cilium [23]. Polycystin-1 has been localized to cell–cell junctions and both apical and basolateral membranes [23, 24]. Polycystin-2 is a resident endoplasmic-reticulum (ER) protein [25] and its trafficking is highly regulated [26, 27, 28, 29]. The differential localization of both polycystins also suggests that these proteins may display different cellular functions either alone or as a protein complex [29, 30]. Several cellular mechanisms have been proposed to explain cyst formation and cyst growth including a change in cell polarity [31], an altered matrix composition [32], and remarkably, a disturbed balance between cell proliferation and apoptosis [33]. The view that polycystin-2 is a potential Ca2+ channel and polycystin-1 is a receptor regulating its activity, suggests that intracellular Ca2+ signaling could be one of the most proximal events in many cellular functions of the polycystins and consequently in the dysfunctional mechanisms that may lead to cyst formation. Clearly, the Ca2+ effects are not limited to the restricted compartment of the cilium but will also involve Ca2+ influx from other parts of the plasma membrane as well as Ca2+ release from the ER. The situation becomes even more complex as polycystin-2 was found to associate with other Ca2+ channels in the plasma membrane (TRPC1 [34, 35] and TRPV4 [36]), and in intracellular membranes (inositol 1,4,5-trisphosphate receptor (IP3R) [37, 38] and ryanodine receptor (RyR) [39]). Moreover, polycystin-1 has been found to interact with basic components of the Ca2+ toolkit such as the IP3R [40] and the stromal interaction molecule-1 (STIM1) [41]. Hence, polycystins may affect Ca2+ signaling in many different ways, including effects on cytosolic or ER Ca2+ concentration, global or local Ca2+ changes, Ca2+ oscillations, intracellular Ca2+-leak pathways or plasma-membrane Ca2+ influx or a combination of these effects. However, the cellular role of polycystins in Ca2+ signaling, and the downstream parameters that may link the disturbed Ca2+ signaling in ADPKD to cyst formation, are not yet understood [42]. In this review, we provide an update of the different effects of polycystins on cellular Ca2+ signaling. We also discuss the current view on the downstream signaling pathways that could be affected by the dysfunctional Ca2+ signals in ADPKD, ultimately leading to a cystic phenotype with increased proliferation and increased apoptosis.

Disturbed cellular Ca2+ fluxes in ADPKD

Cilium and plasma membrane

Polycystin-1 and -2 can form heteromeric complexes in vivo [43]. Importantly, co-expression of both proteins in Chinese hamster ovary (CHO) cells promoted the translocation of polycystin-2 to the plasma membrane and the complex produced a Ca2+-permeable non-selective cation channel [21]. Neither of the polycystins alone produced an ion current, while disease-associated mutants that are incapable of heterodimerization did not result in channel activity. Heterologous expression of both proteins resulted in the formation of a plasmalemmal ion-channel complex in neurons as well as in kidney cells, in which polycystin-2 activation occurred through structural rearrangement of polycystin-1 [14]. An important finding was that both proteins co-localize in the primary cilia of epithelial cells, where their role could be to promote mechano-sensation and fluid-flow sensation [22, 44] (Fig. 1). Cells isolated from transgenic mice that lack functional polycystin-1 formed cilia, but did not increase Ca2+ influx in response to physiological fluid flow. Inhibitory antibodies directed against polycystin-2 similarly abolished the flow response in wild-type cells. Defects in proteins involved in the function or structure of primary cilia such as cystin, polaris, inversin, and kinesin-II also cause polycystic kidney diseases [45]. Fluid shear-force bending of the cilium causes the influx of Ca2+ through mechanically sensitive channels in the ciliary membrane [46]. The Ca2+ signal could then be further amplified by Ca2+ release from IP3Rs or RyRs via a Ca2+-induced Ca2+-release (CICR) mechanism. This view proposes a dysregulated Ca2+ influx as an important first step in the initiation of cystogenesis [47].
Fig. 1

Major players controlling cellular Ca2+ signaling by polycystins. Polycystin-1 (PC1) and polycystin-2 (PC2) form a signaling complex in the cilium that mediates Ca2+ influx via PC2, possibly in response to mechanical stimuli. Also TRPV4, TRPC1, and TRPC4 interact with PC2 and could play a role in mechano-sensitive Ca2+ influx. PC2 is also present in the ER where it directly interacts with the IP3R and in cardiac cells also with the RyR2. PC2 behaves as a Ca2+-induced Ca2+-release channel and thereby amplifies IP3-induced Ca2+ release. The RyR2 is activated by Ca2+ influx via voltage-operated Ca2+ channels and is inhibited by PC2. Ca2+ leak via PC2 may be controlled by other proteins such as syntaxin-5. PC1 activates the PI3-K/AKT signaling. This leads (by as-yet-unresolved mechanisms) to an increase in the STIM1-IP3R interaction, which reduces the interaction between the IP3R and PC2 with possibly a translocation of PC2 to the plasma membrane. PC1 and PC2 compete for the same binding site on the IP3R. PC1 dysfunction leads to strengthening of the IP3R-PC2 interaction and remodeling of the Ca2+ fluxes with an increase of IICR, more ER Ca2+ depletion, and Ca2+ influx via activation of SOCE. PC1 also negatively modulates agonist-evoked NCCE activity through a still undefined mechanism. Loss of function of PC1 causes an increase in NCCE-channel activity leading to Ca2+ oscillations. PC1/PC2 polycystin-1/-2, NCCE non-capacitive Ca2+ entry, ΔV voltage change over the plasma membrane, VOCC voltage-operated Ca2+ channel. Inhibitory and stimulatory mechanisms are represented by red and green arrows, respectively; the purple arrow represents the trafficking of PC2; dotted lines indicate that the mechanisms are as yet undefined

There has been some confusion regarding the structural model for the polycystin-1/-2 complex. A newly identified coiled-coil domain in the C-terminus of polycystin-2 (a.a. 839–873), different from a more upstream coiled-coil domain (a.a. 772–796) [19], has been proposed to mediate assembly into a homotrimer to which a single coiled-coil domain in the C-terminus of polycystin-1 (a.a. 4214–4248) can bind [48, 49]. Other evidence, obtained by atomic force microscopy, however, showed that the polycystin-1/-2 complex assembles as a tetramer with a 2:2 stoichiometry [50]. The latter is more in line with recently described homo- and heteromeric polycystin-2 channel properties suggesting fourfold symmetry [35, 36, 51]. Differences between both models may be due to different structural properties of the helix containing a coiled-coil-domain motif, which may oligomerize differently as an isolated peptide than when embedded in the folded protein [52]. Deletion of this polycystin-2 coiled-coil domain (referred to as CC2 domain) indicated that although this domain is required for heterotypic interaction with polycystin-1, it does not represent the binding site itself [52]. In agreement with earlier studies [19, 48], the domain responsible for binding was found distal from CC2 (a.a. 872–895). Furthermore, there is evidence for a dimerization site in polycystin-2, N-terminally located of the first transmembrane domain, which regulates channel tetramerization [53]. Although CC2 is considered an assembly domain, it does not seem to have a prominent role in the self-association of polycystin-2 [52]. Polycystin-2 channels with CC2 deletions still tetramerize [52], and C-terminal mutants can co-immunoprecipitate full-length polycystin-2 [53]. The role of the C-terminus of polycystin-2 may therefore be to provide an essential scaffolding platform for heteromeric assembly with other channel proteins, including polycystin-1 [19], TRPC1 [34], TRPV4 [36], and the IP3R [37].

The polycystin-2 C-terminus is important for the regulation of the Ca2+-channel activity [54, 55, 56]. An EF-hand motif was identified connected by a linker to a coiled-coil domain overlapping with CC2 [54]. An affinity for Ca2+ in the micromolar range was found for the EF-hand domain by isothermal titration calorimetry. This region may therefore sense local Ca2+ concentration changes and operate as a Ca2+-sensitive switch with a role in proper folding and oligomerization of polycystin-2 [54] and subsequent channel gating [56].

Polycystin-2 can form spontaneously active nonselective cation channels in lipid bilayers [35, 57, 58]. Analysis of the channel properties revealed a high-conductance, nonselective, voltage-dependent cation channel [58]. Using various organic cations of different size, the pore diameter was estimated to be at least 1.1 nm [59]. Heterologous expression in Xenopus oocytes revealed a channel that is sensitive to changes of the cytosolic Ca2+ concentration [60]. Spontaneous activity of polycystin-2 was, however, not always obtained upon heterologous expression of polycystin-2 and polycystin-1 [48], which clearly illustrates the difficulty in identifying the physiological activation mechanisms of polycystin-2 or of the polycystin-1/-2 complex. An even larger complexity is suggested from the observations that polycystin-2 may associate and perhaps form heteromeric channels with other TRP-family members such as TRPC1 [34, 35, 51], TRPC4 [61], and TRPV4 [36] (Fig. 1). The function and regulation of polycystin-2 at the plasma membrane downstream of mechanical stimulation, cell-surface receptors, and cell adhesion, were recently discussed in an excellent review [12]. A role for polycystin-2 as a mechanosensitive channel has been suggested from measurements of changes in the cytosolic Ca2+ concentration in response to fluid flow [22, 62, 63, 64]. Also, regulation of polycystin-2-channel activity by environmental signals such as hydrostatic and osmotic pressure [65] and by cytoskeletal [66] and microtubular [67] elements in the human syncytiotrophoblast supports such a role. Mechanosensitivity of polycystin-2 may result from its interaction with TRPV4, which was required for fluid flow-induced Ca2+ entry in Madin–Darby canine kidney (MDCK) cells [36]. Loss of TRPV4, however, did not result in cyst formation, which suggests that mechanosensitive activation of this channel complex alone is not sufficient for cyst formation [36]. Polycystin-2 can also function as a bona fide receptor-operated channel downstream of epidermal growth factor (EGF) receptor activation [68]. EGF-induced activation of polycystin-2 required the activation of phospholipase C (PLC). Polycystin-2 interacted with PLC-γ2 and colocalized in the primary cilium with the EGF receptor and phosphatidyl inositol 4,5-bisphosphate (PIP2) [68]. EGF-induced activation of PIP2 breakdown resulted in the relieve of PIP2-mediated inhibition of polycystin-2 [68]. The localization of the EGF receptor in the primary cilium could represent a sensitization of the polycystin-2-channel activity with implications for cilium-based mechano-transduction, as it may reduce its threshold for activation by mechanical stimulation [12]. Channel activity of polycystin-2 complexed with TRPC1 but not with polycystin-1 could also be activated in response to PLC-coupled bradykinin-receptor stimulation [51]. This polycystin-2/TRPC1 channel with distinct properties from the polycystin-1/-2 complex has implications in mechano-sensation and cilium-based Ca2+ signaling [51]. Homologs of polycystin-1 and -2 have been shown to form receptor channel complexes acting as sour-taste receptors [69]. As there is increasing evidence from several gene-inactivation studies indicating that cilium-mediated mechano-transduction is not alone responsible for cyst formation, receptor-operated activation may play an important role [36, 51, 70, 71, 72]. A combined mechanism of flow-dependent delivery of a ligand would thereby become an intriguing possibility [13].

Intracellular membranes

The intracellular distribution of polycystin-2 is very complex, with the largest pool in the ER in addition to its localization at the plasma membrane and in more restricted domains such as the primary cilium and mitotic spindles as discussed in several reviews [3, 27, 73]. Next to its role as a plasma-membrane Ca2+ channel and its ciliary function in complex with polycystin-1, polycystin-2 was proposed to have a function in intracellular Ca2+ release [25, 58]. Other findings, however, suggested that whereas heterologous expression of polycystin-2 showed a predominant ER localization, endogenous polycystin-2 was found primarily in the cilium and plasma membrane of mouse inner medullary collecting duct (IMCD) cells and in MDCK cells [74]. The long-standing controversy about this differential distribution has been clarified to some extent by the identification of specific signal sequences and trafficking proteins [3, 30, 60, 75]. A stretch of acidic amino acids in the C-terminus of polycystin-2 functions as an ER-retention signal by binding phosphofurin acidic cluster-sorting proteins (PACS-1 and -2) [25, 28]. Binding of PACS-1 and PACS-2 requires polycystin-2 phosphorylation by casein kinase II (CK-II) at Ser 812, and mediates retrieval back to the trans-Golgi network (PACS-1) and the ER (PACS-2), respectively [28]. Prevention of this phosphorylation in the Caenorhabditis elegans polycystin-2 homologue promoted its translocation to the cilium [76]. Polycystin-2 interactor Golgi- and ER-associated protein (PIGEA-14) is another regulator of polycystin-2 trafficking, causing its movement to a putative trans-Golgi compartment [77]. Plasma-membrane, but not cilia, localization of polycystin-2 is regulated by glycogen synthase kinase 3 (GSK3) phosphorylation of Ser 76 in the N-terminus [78]. In the presence of specific GSK3 inhibitors, the lateral plasma-membrane pool of endogenous polycystin-2 redistributes into an intracellular compartment in MDCK cells without any change in primary-cilia localization [78]. Furthermore, the N-terminus of polycystin-2 contains a motif (R6V7xP8), which is required for localization in the cilia [79]. Cyst cells expressing an ADPKD-associated polycystin-1 mutant had decreased amounts of both polycystin-1 and -2 in the primary cilium, indicating that impairing the function of one protein negatively affects the localization of the other [80].

An interaction between the C-termini of polycystin-1 and polycystin-2 is considered to be important for activation of the Ca2+-channel activity [14, 21]. This does not necessary require a co-localization in the same membrane, and a model for interaction with polycystin-2 either localized in the plasma membrane or in the ER has been proposed [47, 81]. The concept that polycystin-2 may be a novel type of intracellular Ca2+-release channel was based on the observation that polycystin-2 exogenously expressed in LLC-PK1 epithelial cells caused a marked augmentation of intracellular Ca2+ release upon vasopressin stimulation [58]. A similar role as an intracellular Ca2+-release channel was also found for the endogenous homologue of polycystin-2 in Caenorhabditis elegans [82]. The open probability of the channel was increased by Ca2+ in the physiological range (0.1–10 μM), whereas higher cytosolic [Ca2+] lowered the open probability [58]. The observation that polycystin-2 may function as a CICR channel was further strengthened by the sensitization towards Ca2+ upon CK-II phosphorylation at the C-terminal S812 site [83]. Polycystin-2-mediated Ca2+ release from the ER required activation of the IP3R [37, 58]. Moreover, it was demonstrated that polycystin-2 and the IP3R physically interact and the C-terminus of polycystin-2 is required for this interaction [37] (Fig. 1). The binding site was further identified as the acidic cluster in the C-terminus of polycystin-2, which interacts with a cluster of basic residues in the N-terminal suppressor domain of the IP3R [38]. Disruption of this molecular interaction by using competitive peptides eliminated the stimulation of IP3-induced Ca2+ release (IICR) by polycystin-2. In both studies, the channel death mutant (D511 V) did not provoke stimulation of IICR, which is a strong indication that polycystin-2 operates as a CICR channel that becomes activated by IICR in the immediate proximity of the IP3R-channel pore. Activation appears to be restricted to a microdomain of IICR as reduction of this microdomain by the fast Ca2+ buffer BAPTA eliminated activation of the CICR via polycystin-2, whereas the slower Ca2+ buffer EGTA did not have such effect [38]. It is conceivable that ER-localized polycystin-2 is silent in resting conditions as inappropriate opening of this channel would represent a Ca2+ leak from the ER eventually resulting in ER depletion and an ER-stress response [84]. At variance with these data, it was observed that exogenous expression of polycystin-2 in HeLa cells increased the ER Ca2+ permeability, which resulted in lowering of the ER Ca2+ content and a decrease in the histamine-evoked Ca2+ response [85]. The IP3R was not required for the polycystin-2-mediated reduction of the ER Ca2+ load, which suggested that polycystin-2 forms an independent ER Ca2+-leak channel [85]. The apparently contradictory results regarding amplification of IICR as a result of CICR via polycystin-2 [37, 38, 58], versus a diminished IICR due to ER Ca2+-store depletion [85], can possibly be reconciled by the cell- and condition-specific factors that regulate activation of polycystin-2 in the ER. Syntaxin-5, an ER- and Golgi-associated t-SNARE that functions in vesicle targeting and fusion, was found to directly interact with polycystin-2 and to inactivate its channel activity [86]. Syntaxin-5 was proposed to have a function in preventing the Ca2+ leak from the ER via polycystin-2. LLC-PK1 cells expressing Δ(5–72) polycystin-2 that lacks the syntaxin-5-binding site had a reduced ER Ca2+ content and a concomitant lower increase in cytosolic [Ca2+] upon agonist stimulation [86]. Polycystin-2 in the ER may therefore play an important role for controlling ER Ca2+ levels and its activity may be tightly controlled. Among the other polycystin-2-interacting proteins, polycystin-1 [87], α-actinin [88], mammalian diaphanous-related forming 1 (mDIA-1) [89], and fibrocystin [90] have been found to modulate polycystin-2′s activity.

Polycystin-2 was also found to bind and regulate the RyR2 in the sarcoplasmic reticulum (SR) of cardiac myocytes [39]. The C-terminus of polycystin-2 functionally inhibited the RyR2 channel and polycystin-2-deficient cardiomyocytes showed changes in store content and Ca2+-release properties. This altered RyR2 function could play a role in the development of cardiovascular abnormalities in ADPKD patients [39].

On the one hand, polycystin-2 can act as a regulator of other ER/SR channels, but on the other hand, it has its own channel properties that may be controlled by different cellular parameters. An obvious candidate for the regulation of polycystin-2′s channel properties in the ER is polycystin-1. As stated above, models were proposed for interaction of polycystin-1 in the plasma membrane with polycystin-2 in the ER [47, 81]. Although it is still unclear what the function could be of polycystin-1 at the level of the ER, there is compelling evidence that a significant amount of polycystin-1 is also localized there [43, 91]. This is particularly the case for shorter C-terminal cleavage forms, which were shown to functionally interact with the IP3R thereby inhibiting IICR [40]. The interaction site was found to be the IP3R ligand-binding domain similarly to the binding site for polycystin-2 but with an opposite effect. It was therefore proposed that polycystin-1 and polycystin-2 both interact with the IP3R in a complementary way to maintain a balance of proper ER-mediated Ca2+ signaling [40]. A different result was obtained by other authors [92], showing that exogenous expression of polycystin-1 in MDCK cells accelerated the decay of ligand-activated cytoplasmic Ca2+ transients. These data were interpreted as due to an inhibition of the Ca2+ leak across the ER membrane. These studies clearly illustrate the importance of polycystins in maintaining proper ER Ca2+ homeostasis [93]. Another unexpected finding, consistent with the reduction of the intracellular Ca2+ responses, was the identification of a P100 C-terminal fragment of polycystin-1 that is localized in the ER and interacts with STIM1 [41]. P100 probably contains the six C-terminal transmembrane domains and the C-terminal tail. It would interact with STIM1 via its coiled-coil domain and thereby interfere with the translocation of STIM1 to the plasma membrane, inhibiting the activation of store-operated Ca2+ currents. This would then lead to decreased store filling and subsequently to diminished agonist-induced Ca2+ transients [41]. It should be noted, however, that the expression of the C-terminal tail of polycystin-1 as a fusion protein yielded an opposite result and led to an increase in the cytosolic Ca2+ concentration and store-operated Ca2+ entry (SOCE) [94, 95]. This discrepancy may be due to a dominant negative effect of the polycystin-1 C-terminus, given the observation that the formation of P100 actually requires the presence of full-size polycystin-1 [41]. The nature of the polycystin-1 cleavage responsible for P100 generation and the significance of this mechanism are as yet unknown, but these findings clearly illustrate the importance of polycystin-1 as well as polycystin-2 for ER Ca2+ signaling. Mechanistically, polycystin-1 was proposed to increase the interaction between the IP3R and STIM1, which thereby inhibited Ca2+ release and SOCE [96] (Fig. 1). This regulation implicated the activation of the phosphatidylinositol 3-kinase (PI3-K)/protein kinase B (AKT) signaling pathway and would act upon a protein complex involving polycystin-2/IP3R/STIM1. It should be pointed out, however, that in a study comparing STIM1−/− and wild-type MEF cells, no evidence was found for a direct interaction between STIM1 and the IP3R, but the effects on IICR were attributed to changes in the connections between the ER and plasma membrane [97].

The effects of polycystin-1 on ER Ca2+ release were mostly obtained by exogenous expression of polycystin-1 or its C-terminal fragments. The properties of endogenous polycystin-1 as obtained from knock-down experiments are much less documented. In studies of polycystin-1 haploinsufficiency in renal cells [98] or in vascular cells [99], the results pointed to a decreased resting cytosolic Ca2+ concentration in the polycystin-1+/− as compared to the wild-type cells. Moreover, vascular smooth-muscle cells from polycystin-1+/− mice exhibited a decreased agonist-induced Ca2+ release as compared to the wild type [99]. This result is in contrast to the data obtained with exogenous polycystin-1 expression, but it is more in line with the general concept that polycystin-1 and polycystin-2 form a functional complex with Ca2+-channel properties. Disturbance of this complex by either polycystin-2 or polycystin-1 knock-out is then expected to result in a decreased Ca2+-release activity. This is exactly what was recently found for the effect on IICR in a model system of plasma membrane-permeabilized cells upon lentiviral knock-down of either or both polycystins [100]. The presence of both polycystins seemed to be required for stimulation of Ca2+ release from the ER and knock-down of either polycystin decreased the apparent sensitivity of IICR [100]. The conflicting results from different groups may be caused by the fact that on the one hand exogenous expression may result in abnormal processing, trafficking and localization, and on the other hand knock-out or knock-down of endogenous genes may result in adaptive responses. For both approaches, the unraveling of the detailed mechanism is presently not at hand, but it becomes increasingly clear that both polycystins are implicated in ER-related Ca2+ fluxes. An interesting view that was presented in a model by the Guggino group [96], proposed a role for polycystin-1 in preventing a phenotype with more IICR and SOCE-mediated Ca2+ fluxes and promoting a situation with more filled stores and inactivated SOCE with Ca2+ influx via plasma membrane (or cilia)-localized polycystin-2 (Fig. 1). While not all data are easily reconciled with this model, it presents the very appealing idea that defective polycystins in ADPKD provoke a shift in the spatial properties of intracellular Ca2+ signals with the appearance of different microdomains with altered cytosolic Ca2+ concentrations, which can then elicit different downstream effects.

Downstream effects of Ca2+ signaling in ADPKD

Effects on cAMP signaling

Disturbed Ca2+ signaling is a proximal event in ADPKD and it directly or indirectly affects several other very important signaling pathways [101]. Among these, an increased cAMP concentration is a common finding in different models of ADPKD and cAMP stimulates cyst fluid and electrolyte secretion [102], possibly involving the stimulation of the cystic fibrosis transmembrane conductance regulator (CFTR) [103]. The reasons for the high cytosolic cAMP concentration in cyst cells are not very well understood. The polycystin proteins may alter the activity of G-protein-coupled receptors, like the V2 vasopressin receptor, that signal via cAMP [102, 104]. A link with cellular Ca2+ homeostasis was proposed via the activity of Ca2+-inhibitable adenylyl cyclase (AC) and/or Ca2+-dependent phosphodiesterase (PDE) [101]. The interaction between cytosolic Ca2+ and cAMP is, however, very complex, as there are nine different genes encoding transmembrane-domain ACs (AC1–9) along with numerous splice variants of the gene encoding soluble ACs, while also the cyclic nucleotide-PDE superfamily consists of over 30 genes [105]. Moreover, different members of these families are sensitive to Ca2+, either directly or via calmodulin. A common theme in the regulation of cAMP production is the pronounced intracellular compartmentalization. Three modes of cAMP microdomain/compartment formation are found: via (a) lipid rafts, (b) A-kinase anchor proteins (AKAPs), and (c) targeting of soluble AC to cellular organelles [105]. It can therefore be anticipated that a relation between polycystin dysfunction and the cAMP levels in ADPKD may be very much linked to specific microdomains either at the plasma membrane or at intracellular membranes and may involve particular AC or PDE isoforms. In this respect, it was recently demonstrated that the primary cilium plays an important role as a subcellular cAMP-signaling compartment [106]. A protein complex comprising AKAP150, AC5/6, and protein kinase A (PKA) was found in primary cilia of renal epithelial cells. Polycystin-2 and PDE4C were further identified as components of this ciliary AKAP complex. Under normal conditions PDE4C would promote the hydrolysis of cAMP and polycystin-2 could provide local accumulation of Ca2+ that inhibits the Ca2+-sensitive AC5 and AC6. Malfunction of polycystin-2 as a Ca2+ channel may reduce the local Ca2+ concentration in the cilium and thereby activate AC5/6. Other mechanisms like mutations of the transcription factor hepatocyte nuclear factor-1ß (HNF-1ß) were found to inhibit the expression of PDE4C and thereby increase cAMP levels [106]. As HNF-1ß also regulates the expression of Pkd2 itself [107], downregulation of polycystin-2 and subsequent impaired ciliary trafficking of the AKAP complex may also contribute to the elevation of cAMP levels [106]. PDE1 isoforms (PDE1a, PDE1b, and PDE1c) are expressed to high levels in the kidney cells [108]. Importantly, these PDE isoforms are also regulated by cytosolic Ca2+, which in ADPKD would result in decreased PDE activity and a higher cAMP concentration [42]. An additional mechanism that could be important in ADPKD is cAMP production related to Ca2+-store depletion and STIM1 translocation [109]. These data are indicative of a mechanism of store-operated cAMP signaling, in which lowering of the Ca2+ concentration in the ER led to recruitment of ACs through a process involving STIM1 [109]. This mechanism was also found in polycystin-2-defective cholangiocytes, where polycystin-2 was suggested to play a role in SOCE activation and in inhibiting the STIM-dependent activation of AC6 [110]. In view of the observation that polycystin-1 expression impairs translocation of STIM to the plasma membrane, this mechanism could also link polycystin-1 defects to increased cAMP signaling in ADPKD [41, 96].

Effects on B-Raf-extracellular signal-regulated kinase (ERK) signaling and cell proliferation (Fig. 2)

In general, cystic epithelia in ADPKD have high levels of cAMP and also of mitogen-activated protein kinase (MAPK) activity. This signaling pathway, involving cAMP-dependent PKA, stimulates the proliferation of cells from ADPKD cysts, but not cells from normal human kidney [111, 112, 113]. In normal cells, cAMP via PKA-mediated phosphorylation inhibits the MAPK pathway by blocking the activation of Raf-1 (Raf-C). In cystic cells, however, cAMP signaling is changed, an effect which is attributed to the low cytosolic Ca2+ concentration [114, 115]. Ca2+ restriction was associated with an elevation in B-Raf protein levels. In these conditions, cAMP stimulates B-Raf/MEK/ERK signaling in a sarcoma (Src)- and Ras-dependent manner. Moreover, the activity of AKT, a negative regulator of B-Raf, was decreased by Ca2+ restriction. Inhibition of AKT or PI3-K also allowed cAMP-dependent activation of B-Raf and ERK at normal Ca2+ levels. These results suggest that Ca2+ restriction causes an inhibition of the PI3-K/AKT pathway, which relieves the inhibition of B-Raf to allow the cAMP growth-stimulated phenotypic switch [112, 114]. The steady-state cytosolic Ca2+ concentration was found to be 20 nM lower in cyst-derived ADPKD cells compared with normal cells. Elevation of the cytosolic Ca2+ concentration in ADPKD cells increased AKT activity and blocked cAMP-dependent B-Raf and ERK activation. Thus, an increase in the cytosolic Ca2+ concentration was able to restore the normal anti-mitogenic response to cAMP [115], while Ca2+-channel inhibition by verapamil accelerated polycystic kidney-disease progression [116]. On the other hand, it was found that down-regulation of polycystin-1 using RNA interference [117] or expression of the dominant-negative polycystin-1 C-terminus [95, 118] resulted in an increase in basal Ca2+ concentration. The differential effects of polycystin-1 expression on the cytosolic Ca2+ concentration and downstream effects could reflect the use of different cell types such as immortalized cells versus primary cells [117].
Fig. 2

Signaling pathways that relate disturbed polycystin-mediated Ca2+ signaling to cell proliferation. Defects in polycystin functions generally lead to a decrease in the cytosolic Ca2+ concentration ([Ca2+]i). This results in an increase in cAMP concentration, probably via changes in Ca2+-dependent phosphodiesterase or Ca2+-dependent adenylate-cyclase activity (not shown). The Ca2+-cAMP link is represented by the box. In the presence of low [Ca2+]i, cAMP becomes pro-proliferative via activation of the Src/Ras/B-Raf/MEK/ERK pathway. Ca2+ restriction causes decreased PI3-K/AKT signaling, which relieves the inhibition of B-Raf. Activation of growth-factor receptors with tyrosine-kinase activity (GFR) also contributes to the stimulation of MAPK/ERK signaling and cell proliferation. Polycystin-1 dysfunction thus upregulates the MAPK/ERK pathway, which results in inactivation of the tuberin complex and increased mTORC1. Cytoplasmic Ca2+ also regulates the mTOR pathway via CaMKKß and AMPK (the question mark indicates that the occurrence of this mechanism was not yet explored in cystic cells). The deregulated Ca2+ signaling switches on canonical Wnt signaling, which activates mTOR via inhibiting GSK3 phosphorylation of tuberin. Another link to cell proliferation may depend on the activation of Ca2+ oscillations and subsequent effects on gene transcription and cyclins via Ca2+-dependent NFAT or via protein kinase Cα (PKCα) signaling. Boxed areas indicate mechanisms not shown in detail. Dotted arrows indicate still-unresolved mechanisms. GFR growth-factor receptor

Effects on mammalian target of rapamycin (mTOR) signaling (Fig. 2)

Cyst-lining epithelial cells exhibit higher levels of mTOR signaling as compared to normal epithelial cells [119]. mTOR is a serine/threonine protein kinase that provides catalytic activity for two distinct multiprotein complexes (mTORC1 and mTORC2). mTORC1 is a metabolic sensor and its activation promotes cell growth and cell proliferation. The effects of mTORC2 include modulation of cell survival, cytoskeletal organization, and cell polarity [120]. Hyperactivity of mTORC1 and possibly also of mTORC2, contributes to cyst formation [121]. Tuberin, the protein product of Tsc2, in a complex with hamartin, the product of Tsc1, is the primary negative regulator of mTORC1. Tuberin is a GTPase-activating protein (GAP), which regulates Rheb, a small G-protein belonging to the Ras superfamily. Hamartin and tuberin form a heterodimer, which converts Rheb-GTP to the inactive Rheb-GDP. Rheb is an activator of mTORC1 and conversion of Rheb to the GDP-bond form inactivates the mTORC1 pathway [120, 121, 122, 123]. The tuberin–hamartin complex is a nodal point for several polycystin-dependent pathways. The cytoplasmic tail of polycystin-1 interacts with tuberin. This may occur via direct interaction with tuberin [119] or indirectly via ERK-dependent phosphorylation and inactivation of the tuberin complex [124]. A prominent activation of the ERK pathway together with cystogenesis was found upon inactivation of the Pkd1 gene in conditional knock-out mice [125]. The regulation may, however, be more complex as tuberin has been reported to be phosphorylated by at least nine distinct protein kinases [126]. Among these are multiple pathways that may be linked to proper functioning of polycystins and some of these are clearly linked to Ca2+ (Fig. 2). As explained above, a potential link with Ca2+ and cAMP may occur via B-Raf/ERK signaling. The lower Ca2+ levels in cystic cells would together with the increased cAMP concentration lead to activation of B-Raf/ERK and subsequent mTORC1 signaling [42, 114, 115]. Another mechanistic input of polycystins on mTORC1 is via ciliar activation of liver kinase B1 (LKB1), which, like the polycystins, is localized in the basal bodies of primary cilia [127]. LKB1 activates AMP-activated protein kinase (AMPK), which then activates tuberin with subsequent negative regulation of mTORC1. This cilium-mediated effect on mTOR was, however, found to be independent of flow-induced Ca2+ transients or AKT [127]. Next to LKB1, however, AMPK activity is also directly linked to the cytosolic Ca2+ concentration by calmodulin-dependent protein kinase kinase ß (CaMKKβ) [128]. The link between the changed cytosolic Ca2+ concentration in cystic cells and mTORC1 via CaMKKβ-dependent regulation of AMPK is, however, not yet established. A relation between AMPK activity and cyst formation was, however, found by using metformin, a drug in wide clinical use as a pharmacological activator of AMPK [129]. Stimulation of AMPK activity by metformin resulted in inhibition of the mTOR pathway and significant arrest of cystic growth in in vitro and ex vivo models of renal cystogenesis [129].

Additional pathways may converge on mTOR signaling in a Ca2+-dependent way. Wnt signaling, which was shown to be regulated by polycystin-1 [130], can activate a ß-catenin-dependent (canonical) and a ß-catenin-independent (non-canonical) pathway. In addition, a Wnt-Ca2+ pathway influences both canonical and non-canonical pathways [131]. Inversin, a ciliar protein, functions as a molecular switch between the different Wnt signaling pathways [132]. It can be speculated that ciliary events as flow-induced Ca2+ influx can switch off the canonical and activate the non-canonical pathway [42]. Over-activation of canonical Wnt and subsequent over-production of activated ß-catenin would promote the polycystic phenotype [133]. This is further supported by many observations showing a link between disturbed polycystin function and enhanced activity of Wnt signaling [130, 134, 135, 136]. In addition, the Wnt pathway is also able to act on mTOR via AMPK and GSK3 [137] (Fig. 2). Tuberin was reported to be a physiological substrate of GSK3, which required priming phosphorylation by AMPK. Canonical Wnt then activates mTOR via inhibiting GSK3 phosphorylation of tuberin [137]. Moreover, GSK3ß was shown to be activated by polycystin-1 [138]. In ADPKD, disturbed polycystin-1 function and disturbed Ca2+ signaling may thus both contribute to a GSK3-dependent increase in mTOR activity [124].

Effects on cell proliferation and apoptosis (Figs. 2, 3)

Kidneys from ADPKD patients have high levels of apoptosis in addition to increased cellular proliferation [139, 140, 141]. This dysregulation of both apoptosis and proliferation may represent a general mechanism for cyst growth and remodeling [140, 142], and the imbalance between pro-apoptotic and pro-proliferative factors was proposed to be critical for the development of cystic kidney disease [143, 144, 145]. Different signaling pathways may be implicated in the abnormal cell-cycle progression. Polycystin-1 activates the JAK-STAT pathway, thereby up-regulating p21 (waf1), an inhibitor of cyclin-dependent kinase (CDK), and thereby inducing cell-cycle arrest in G0/G1. This process requires polycystin-2 as an essential cofactor [146]. A decrement of p21 in cystic kidneys as compared to non-cystic kidneys was demonstrated in humans and rat models [147]. Roscovitine, which has been shown to arrest progression in a murine model of polycystic kidney disease, increases p21 levels and decreases renal tubular epithelial-cell proliferation [147, 148]. Renal tubular epithelial cells exposed to “low” concentrations of roscovitine showed minimal apoptosis in association with markedly increased levels of the anti-apoptotic protein p21, and these cells became senescent. Conversely, cells exposed to “high” levels of roscovitine became apoptotic [149]. Tubular-cell apoptosis occurs in most animal models of ADPKD like the SBM mouse [150, 151] and the Han:SPRD rat model [152], as well as in kidneys from ADPKD patients [139, 140, 141]. Mice deficient in the anti-apoptotic Bcl-2 gene develop polycystic kidney disease characterized by dilated proximal and distal tubular segments and hyper-proliferation of the epithelium and interstitium [153, 154]. While ablation of the pro-apoptotic Bim prevented the development of polycystic kidney disease in mice deficient in Bcl-2 [155], this was not the case in polycystin-1-deficient mice. This indicates that loss of Bcl-2 or loss of polycystin-1 elicit polycystic kidney disease through different mechanisms [156]. Similarly, deletion of another anti-apoptotic gene, the AP2ß transcription factor, in AP2ß−/− mouse resulted in polycystic kidney disease with concomitant down-regulation of anti-apoptotic Bcl-2-family proteins and massive apoptotic cell death [157]. A direct cause-and-effect relationship between cyst formation and apoptosis was demonstrated in Han:SPRD rats using caspase inhibitors. Caspase inhibition was found to reduce tubular apoptosis and proliferation and to slow disease progression in polycystic kidney disease [158]. A marked increase in caspase-3 and -7 activity has been reported in the Han:SPRD rat [143, 159, 160], and targeted caspase-3-gene deletion prolongs survival [161]. In the SBM mouse that overexpresses the proto-oncogen c-myc, both proliferative and apoptotic indexes were highly increased, reflecting a critical imbalance in c-myc regulation of the opposing processes of cell proliferation and apoptosis [162]. Overexpression of c-myc was found in cystic tissue and is supposed to play a role in the dysregulation of both proliferation and apoptosis in ADPKD [140, 162, 163, 164, 165].
Fig. 3

Signaling pathways relating disturbed polycystin-mediated Ca2+ signaling to apoptotic cell death. Disruption of PC1 function leads to a phenotype with low intracellular Ca2+ concentration and high cAMP concentration that showed a mitogenic response towards cAMP and down-regulation of PI3-K/AKT. This provokes a profound remodeling of the relation between Ca2+ release and Ca2+ influx via an IP3R/PC2/STIM1 protein complex. Decreased AKT signaling would strengthen the IP3R-PC2 interaction and lead to increased IICR, translocation of STIM1 to the plasma membrane, and refilling of the ER via SOCE. AKT can also directly phosphorylate the IP3R thereby inhibiting its activity. A decreased AKT activity in cystic cells would thereby relieve the inhibition of the IP3R and contribute to the increase in IICR. PC2 can function as an ER Ca2+-leak channel and a loss of function would therefore increase the ER Ca2+ content and IICR. The increased IICR via these different mechanisms ultimately leads to increased Ca2+ transfer from the ER to the mitochondria. Mitochondrial Ca2+ overload is a very important determinant of Ca2+-dependent apoptosis. Boxed areas indicate mechanisms not shown in detail. Dotted arrows indicate still unresolved mechanisms. IP3R-P: IP3R phosphorylated by AKT (S2681 in IP3R1)

Ca2+ signaling is implicated in the phenotypic feature of ADPKD cells showing elevated rates of both proliferation and apoptosis, but the downstream mechanisms are not fully resolved. It was found that polycystin-1 induces resistance to apoptosis and normal tubulogenesis through the PI3-K/AKT pathway [166] (Fig. 3). These data are consistent with observations that loss of polycystin-1 function results in changes in cytosolic Ca2+ concentration, down-regulation of PI3-K/AKT and activation of B-Raf/ERK in ADPKD cysts [114]. As already outlined above, the disturbed intracellular Ca2+ signaling could be a primary event in ADPKD and may be responsible for the switch to a proliferative phenotype with an elevation in B-Raf protein levels and cAMP-stimulated, Ras-dependent activation of B-Raf and ERK [114, 115]. Also, a PKD2 transgenic mouse model resulted in renal-cys formation via B-Raf signaling, probably by acting as a dominant negative modulator for polycystin function and downstream Ca2+ signals [167]. Pkd2+/− vascular smooth-muscle cells also have an abnormal phenotype with a defective Ca2+ signaling with decreased levels of the cytosolic Ca2+ and an increased cellular cAMP concentration, which is probably underpinning increased proliferation and apoptosis [168]. The low cytosolic Ca2+ concentration apparently provoked increased proliferation in these vascular smooth-muscle cells but the effect in this cell type was independent of cAMP/B-Raf signaling [168].

A divergent mechanism was proposed, in which disturbed polycystin-1 function affected cell proliferation by an increase in intracellular Ca2+ signaling in the form of activation of Ca2+ oscillations [117] (Fig. 2). Serum treatment of HEK293 cells with down-regulated polycystin-1 or of cystic cells expressing mutated polycystin-1 resulted in increased oscillatory activity of the cytosolic Ca2+ concentration which led to activation of cell proliferation. The proposed mechanism involved non-capacitative Ca2+ entry (NCCE), which was proposed to be negatively regulated by polycystin-1. The loss of polycystin-1 resulted in NCCE activation and increased Ca2+ oscillations. The downstream effects were related to activation of the calcineurin/nuclear factor of activated T cells (NFAT) pathway. The explanation could be that Ca2+ oscillations rather than the basal Ca2+ concentration are crucial for activation of the NFAT-dependent cell proliferation [117].

Another important factor, particularly for the increased apoptosis in ADPKD, could be the regulation of the ER Ca2+ content by polycystins [84] (Fig. 3). The ER Ca2+ content is determined by the activity of Ca2+ pumps and by the Ca2+-leak rate via different pathways. The resulting ER Ca2+ load is a primary determinant of the extent of ER-to-mitochondrial Ca2+ transfer and pro-apoptotic Ca2+ signaling [84]. Polycystin-2 in the ER may act as a Ca2+-leak pathway and in this way control the degree of ER Ca2+ filling [85]. Normal polycystin-2 functioning would then reduce Ca2+ release from the ER in response to apoptotic stimuli, and conversely, its loss in ADPKD would lead to an increased apoptosis [85]. Although this mechanism may provide a simple molecular explanation for the increased apoptosis rate in ADPKD upon loss of polycystin-2 function, the situation may be more complex. As discussed above, polycystin-2 activity and its modulation of ER Ca2+ are probably tightly regulated by many other cellular factors and interacting proteins. Not only is polycystin-2 a Ca2+ channel but it also interacts with the two main intracellular Ca2+-release channels, IP3Rs and RyRs, and with various plasma-membrane TRP channels. Polycystin-1 controls the activity of polycystin-2 directly and also in an indirect way via PI3-K/AKT signaling. Decreased PI3-K/AKT signaling in ADPKD would thereby lead to a profound remodeling with increased IICR and SOCE (Fig. 3). This results from activation of Ca2+ release via polycystin-2, but also from a higher IP3R activity resulting from the relieve of the brake imposed by AKT-mediated phosphorylation [169]. Increased IICR, particularly at the contact sites of the ER and mitochondria, constitutes a strong apoptotic signal [84, 170].

In conclusion, disturbed or remodeled cellular Ca2+ signaling is clearly a very early event in the development of the cystic phenotype of renal cells. This phenotype is characterized by a concomitant activation of both cell proliferation and apoptotic cell death. Despite the increased proliferation as an invariable component of cystogenesis, there is seldom progression towards renal carcinoma [171]. Overexpression of polycystin-1 provoked apoptosis in different cancer cell lines, and it is tempting to speculate that polycystins, by controlling the balance between proliferation and cell death, may play a role in preventing malignant transformation [171]. ADPKD epithelial cells are thereby characterized by a modest degree of cell proliferation together with a proportional increase in apoptosis [139, 140, 146, 153, 157, 172]. Both polycystins are closely involved in cellular Ca2+ signaling by direct or indirect interaction with many proteins of the cellular Ca2+ toolkit. It becomes increasingly evident that polycystin dysfunctions lead to a profound remodeling of cellular Ca2+ signaling and provoke changes in the spatio-temporal modes of Ca2+ signaling. This could lead to changes in the occurrence of different Ca2+-signaling microdomains located at the cilia or at the ER-mitochondria junctions, and it could lead to oscillatory Ca2+ signals that may evoke nuclear responses. It will be a challenge for future research to experimentally detect the subcellular Ca2+-signaling microdomains and to identify their downstream responses that result in the increased proliferation and increased apoptosis responses, which are characteristic for the cystic phenotype.

Notes

Open Access

This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

  1. 1.
    Chang MY, Ong AC (2008) Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and treatment. Nephron Physiol 108:1–7CrossRefGoogle Scholar
  2. 2.
    Harris PC, Torres VE (2009) Polycystic kidney disease. Annu Rev Med 60:321–337PubMedCrossRefGoogle Scholar
  3. 3.
    Chapin HC, Caplan MJ (2010) The cell biology of polycystic kidney disease. J Cell Biol 191:701–710PubMedCrossRefGoogle Scholar
  4. 4.
    Hofherr A, Kottgen M (2011) TRPP channels and polycystins. Adv Exp Med Biol 704:287–313PubMedCrossRefGoogle Scholar
  5. 5.
    Sutters M (2006) The pathogenesis of autosomal dominant polycystic kidney disease. Nephron Exp Nephrol 103:e149–e155PubMedCrossRefGoogle Scholar
  6. 6.
    Qamar S, Vadivelu M, Sandford R (2007) TRP channels and kidney disease: lessons from polycystic kidney disease. Biochem Soc Trans 35:124–128PubMedCrossRefGoogle Scholar
  7. 7.
    Kottgen M (2007) TRPP2 and autosomal dominant polycystic kidney disease. Biochim Biophys Acta 1772:836–850PubMedCrossRefGoogle Scholar
  8. 8.
    Weimbs T (2007) Polycystic kidney disease and renal injury repair: common pathways, fluid flow, and the function of polycystin-1. Am J Physiol Renal Physiol 293:F1423–F1432PubMedCrossRefGoogle Scholar
  9. 9.
    Witzgall R (2007) TRPP2 channel regulation. Handb Exp Pharmacol 179:363–375PubMedCrossRefGoogle Scholar
  10. 10.
    Tsiokas L, Kim S, Ong EC (2007) Cell biology of polycystin-2. Cell Signal 19:444–453PubMedCrossRefGoogle Scholar
  11. 11.
    Zhou J (2009) Polycystins and primary cilia: primers for cell cycle progression. Annu Rev Physiol 71:83–113PubMedCrossRefGoogle Scholar
  12. 12.
    Tsiokas L (2009) Function and regulation of TRPP2 at the plasma membrane. Am J Physiol Renal Physiol 297:F1–F9PubMedCrossRefGoogle Scholar
  13. 13.
    Gallagher AR, Germino GG, Somlo S (2010) Molecular advances in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis 17:118–130PubMedCrossRefGoogle Scholar
  14. 14.
    Delmas P, Nauli SM, Li X, Coste B, Osorio N, Crest M, Brown DA, Zhou J (2004) Gating of the polycystin ion channel signaling complex in neurons and kidney cells. Faseb J 18:740–742PubMedGoogle Scholar
  15. 15.
    Delmas P (2005) Polycystins: polymodal receptor/ion-channel cellular sensors. Pflugers Arch 451:264–276PubMedCrossRefGoogle Scholar
  16. 16.
    Nims N, Vassmer D, Maser RL (2003) Transmembrane domain analysis of polycystin-1, the product of the polycystic kidney disease-1 (PKD1) gene: evidence for 11 membrane-spanning domains. Biochemistry 42:13035–13048PubMedCrossRefGoogle Scholar
  17. 17.
    Qian F, Boletta A, Bhunia AK, Xu H, Liu L, Ahrabi AK, Watnick TJ, Zhou F, Germino GG (2002) Cleavage of polycystin-1 requires the receptor for egg jelly domain and is disrupted by human autosomal-dominant polycystic kidney disease 1-associated mutations. Proc Natl Acad Sci USA 99:16981–16986PubMedCrossRefGoogle Scholar
  18. 18.
    Qian F, Germino FJ, Cai Y, Zhang X, Somlo S, Germino GG (1997) PKD1 interacts with PKD2 through a probable coiled-coil domain. Nat Genet 16:179–183PubMedCrossRefGoogle Scholar
  19. 19.
    Tsiokas L, Kim E, Arnould T, Sukhatme VP, Walz G (1997) Homo- and heterodimeric interactions between the gene products of PKD1 and PKD2. Proc Natl Acad Sci USA 94:6965–6970PubMedCrossRefGoogle Scholar
  20. 20.
    Mochizuki T, Wu G, Hayashi T, Xenophontos SL, Veldhuisen B, Saris JJ, Reynolds DM, Cai Y, Gabow PA, Pierides A, Kimberling WJ, Breuning MH, Deltas CC, Peters DJ, Somlo S (1996) PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 272:1339–1342PubMedCrossRefGoogle Scholar
  21. 21.
    Hanaoka K, Qian F, Boletta A, Bhunia AK, Piontek K, Tsiokas L, Sukhatme VP, Guggino WB, Germino GG (2000) Co-assembly of polycystin-1 and -2 produces unique cation-permeable currents. Nature 408:990–994PubMedCrossRefGoogle Scholar
  22. 22.
    Nauli SM, Alenghat FJ, Luo Y, Williams E, Vassilev P, Li X, Elia AE, Lu W, Brown EM, Quinn SJ, Ingber DE, Zhou J (2003) Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet 33:129–137PubMedCrossRefGoogle Scholar
  23. 23.
    Menezes LF, Germino GG (2009) Polycystic kidney disease, cilia, and planar polarity. Methods Cell Biol 94:273–297PubMedCrossRefGoogle Scholar
  24. 24.
    Scheffers MS, van der Bent P, Prins F, Spruit L, Breuning MH, Litvinov SV, de Heer E, Peters DJ (2000) Polycystin-1, the product of the polycystic kidney disease 1 gene, co-localizes with desmosomes in MDCK cells. Hum Mol Genet 9:2743–2750PubMedCrossRefGoogle Scholar
  25. 25.
    Cai Y, Maeda Y, Cedzich A, Torres VE, Wu G, Hayashi T, Mochizuki T, Park JH, Witzgall R, Somlo S (1999) Identification and characterization of polycystin-2, the PKD2 gene product. J Biol Chem 274:28557–28565PubMedCrossRefGoogle Scholar
  26. 26.
    Scheffers MS, Le H, van der Bent P, Leonhard W, Prins F, Spruit L, Breuning MH, de Heer E, Peters DJ (2002) Distinct subcellular expression of endogenous polycystin-2 in the plasma membrane and Golgi apparatus of MDCK cells. Hum Mol Genet 11:59–67PubMedCrossRefGoogle Scholar
  27. 27.
    Witzgall R (2005) Polycystin-2–an intracellular or plasma membrane channel? Naunyn Schmiedebergs Arch Pharmacol 371:342–347PubMedCrossRefGoogle Scholar
  28. 28.
    Kottgen M, Walz G (2005) Subcellular localization and trafficking of polycystins. Pflugers Arch 451:286–293PubMedCrossRefGoogle Scholar
  29. 29.
    Kottgen M, Benzing T, Simmen T, Tauber R, Buchholz B, Feliciangeli S, Huber TB, Schermer B, Kramer-Zucker A, Hopker K, Simmen KC, Tschucke CC, Sandford R, Kim E, Thomas G, Walz G (2005) Trafficking of TRPP2 by PACS proteins represents a novel mechanism of ion channel regulation. EMBO J 24:705–716PubMedCrossRefGoogle Scholar
  30. 30.
    Fu X, Wang Y, Schetle N, Gao H, Putz M, von Gersdorff G, Walz G, Kramer-Zucker AG (2008) The subcellular localization of TRPP2 modulates its function. J Am Soc Nephrol 19:1342–1351PubMedCrossRefGoogle Scholar
  31. 31.
    Wilson PD (1997) Epithelial cell polarity and disease. Am J Physiol Renal Physiol 272:F434–F442Google Scholar
  32. 32.
    Calvet JP (1993) Polycystic kidney disease: primary extracellular matrix abnormality or defective cellular differentiation? Kidney Int 43:101–108PubMedCrossRefGoogle Scholar
  33. 33.
    Gallagher AR, Hidaka S, Gretz N, Witzgall R (2002) Molecular basis of autosomal-dominant polycystic kidney disease. Cell Mol Life Sci 59:682–693PubMedCrossRefGoogle Scholar
  34. 34.
    Tsiokas L, Arnould T, Zhu C, Kim E, Walz G, Sukhatme VP (1999) Specific association of the gene product of PKD2 with the TRPC1 channel. Proc Natl Acad Sci USA 96:3934–3939PubMedCrossRefGoogle Scholar
  35. 35.
    Zhang P, Luo Y, Chasan B, Gonzalez-Perrett S, Montalbetti N, Timpanaro GA, Cantero Mdel R, Ramos AJ, Goldmann WH, Zhou J, Cantiello HF (2009) The multimeric structure of polycystin-2 (TRPP2): structural-functional correlates of homo- and hetero-multimers with TRPC1. Hum Mol Genet 18:1238–1251PubMedCrossRefGoogle Scholar
  36. 36.
    Kottgen M, Buchholz B, Garcia-Gonzalez MA, Kotsis F, Fu X, Doerken M, Boehlke C, Steffl D, Tauber R, Wegierski T, Nitschke R, Suzuki M, Kramer-Zucker A, Germino GG, Watnick T, Prenen J, Nilius B, Kuehn EW, Walz G (2008) TRPP2 and TRPV4 form a polymodal sensory channel complex. J Cell Biol 182:437–447PubMedCrossRefGoogle Scholar
  37. 37.
    Li Y, Wright JM, Qian F, Germino GG, Guggino WB (2005) Polycystin 2 interacts with type I inositol 1,4,5-trisphosphate receptor to modulate intracellular Ca2+ signaling. J Biol Chem 280:41298–41306PubMedCrossRefGoogle Scholar
  38. 38.
    Sammels E, Devogelaere B, Mekahli D, Bultynck G, Missiaen L, Parys JB, Cai Y, Somlo S, De Smedt H (2010) Polycystin-2 activation by inositol 1,4,5-trisphosphate-induced Ca2+ release requires its direct association with the inositol 1,4,5-trisphosphate receptor in a signaling microdomain. J Biol Chem 285:18794–18805PubMedCrossRefGoogle Scholar
  39. 39.
    Anyatonwu GI, Estrada M, Tian X, Somlo S, Ehrlich BE (2007) Regulation of ryanodine receptor-dependent calcium signaling by polycystin-2. Proc Natl Acad Sci USA 104:6454–6459PubMedCrossRefGoogle Scholar
  40. 40.
    Li Y, Santoso NG, Yu S, Woodward OM, Qian F, Guggino WB (2009) Polycystin-1 interacts with inositol 1,4,5-trisphosphate receptor to modulate intracellular Ca2+ signaling with implications for polycystic kidney disease. J Biol Chem 284:36431–36441PubMedCrossRefGoogle Scholar
  41. 41.
    Woodward OM, Li Y, Yu S, Greenwell P, Wodarczyk C, Boletta A, Guggino WB, Qian F (2010) Identification of a polycystin-1 cleavage product, P100, that regulates store operated Ca2+ entry through interactions with STIM1. PLoS ONE 5:e12305PubMedCrossRefGoogle Scholar
  42. 42.
    Abdul-Majeed S, Nauli SM (2011) Calcium-mediated mechanisms of cystic expansion. Biochim Biophys Acta 1812:1281–1290PubMedCrossRefGoogle Scholar
  43. 43.
    Newby LJ, Streets AJ, Zhao Y, Harris PC, Ward CJ, Ong AC (2002) Identification, characterization, and localization of a novel kidney polycystin-1-polycystin-2 complex. J Biol Chem 277:20763–20773PubMedCrossRefGoogle Scholar
  44. 44.
    Praetorius HA, Spring KR (2003) The renal cell primary cilium functions as a flow sensor. Curr Opin Nephrol Hypertens 12:517–520PubMedCrossRefGoogle Scholar
  45. 45.
    Ong AC, Wheatley DN (2003) Polycystic kidney disease–the ciliary connection. Lancet 361:774–776PubMedCrossRefGoogle Scholar
  46. 46.
    Praetorius HA, Spring KR (2001) Bending the MDCK cell primary cilium increases intracellular calcium. J Membr Biol 184:71–79PubMedCrossRefGoogle Scholar
  47. 47.
    Delmas P, Padilla F, Osorio N, Coste B, Raoux M, Crest M (2004) Polycystins, calcium signaling, and human diseases. Biochem Biophys Res Commun 322:1374–1383PubMedCrossRefGoogle Scholar
  48. 48.
    Yu Y, Ulbrich MH, Li MH, Buraei Z, Chen XZ, Ong AC, Tong L, Isacoff EY, Yang J (2009) Structural and molecular basis of the assembly of the TRPP2/PKD1 complex. Proc Natl Acad Sci USA 106:11558–11563PubMedCrossRefGoogle Scholar
  49. 49.
    Zhu J, Yu Y, Ulbrich MH, Li MH, Isacoff EY, Honig B, Yang J (2011) Structural model of the TRPP2/PKD1 C-terminal coiled-coil complex produced by a combined computational and experimental approach. Proc Natl Acad Sci USA 108:10133–10138PubMedCrossRefGoogle Scholar
  50. 50.
    Kobori T, Smith GD, Sandford R, Edwardson JM (2009) The transient receptor potential channels TRPP2 and TRPC1 form a heterotetramer with a 2:2 stoichiometry and an alternating subunit arrangement. J Biol Chem 284:35507–35513PubMedCrossRefGoogle Scholar
  51. 51.
    Bai CX, Giamarchi A, Rodat-Despoix L, Padilla F, Downs T, Tsiokas L, Delmas P (2008) Formation of a new receptor-operated channel by heteromeric assembly of TRPP2 and TRPC1 subunits. EMBO Rep 9:472–479PubMedCrossRefGoogle Scholar
  52. 52.
    Giamarchi A, Feng S, Rodat-Despoix L, Xu Y, Bubenshchikova E, Newby LJ, Hao J, Gaudioso C, Crest M, Lupas AN, Honore E, Williamson MP, Obara T, Ong AC, Delmas P (2010) A polycystin-2 (TRPP2) dimerization domain essential for the function of heteromeric polycystin complexes. EMBO J 29:1176–1191PubMedCrossRefGoogle Scholar
  53. 53.
    Feng S, Okenka GM, Bai CX, Streets AJ, Newby LJ, DeChant BT, Tsiokas L, Obara T, Ong AC (2008) Identification and functional characterization of an N-terminal oligomerization domain for polycystin-2. J Biol Chem 283:28471–28479PubMedCrossRefGoogle Scholar
  54. 54.
    Celic A, Petri ET, Demeler B, Ehrlich BE, Boggon TJ (2008) Domain mapping of the polycystin-2 C-terminal tail using de novo molecular modeling and biophysical analysis. J Biol Chem 283:28305–28312PubMedCrossRefGoogle Scholar
  55. 55.
    Petri ET, Celic A, Kennedy SD, Ehrlich BE, Boggon TJ, Hodsdon ME (2010) Structure of the EF-hand domain of polycystin-2 suggests a mechanism for Ca2+-dependent regulation of polycystin-2 channel activity. Proc Natl Acad Sci USA 107:9176–9181PubMedCrossRefGoogle Scholar
  56. 56.
    Celic AS, Petri ET, Benbow J, Hodsdon ME, Ehrlich BE, Boggon TJ (2012) Calcium-induced conformational changes in C-terminal tail of polycystin-2 are necessary for channel gating. J Biol Chem 287:17232–17240PubMedCrossRefGoogle Scholar
  57. 57.
    Gonzalez-Perrett S, Kim K, Ibarra C, Damiano AE, Zotta E, Batelli M, Harris PC, Reisin IL, Arnaout MA, Cantiello HF (2001) Polycystin-2, the protein mutated in autosomal dominant polycystic kidney disease (ADPKD), is a Ca2+-permeable nonselective cation channel. Proc Natl Acad Sci USA 98:1182–1187PubMedCrossRefGoogle Scholar
  58. 58.
    Koulen P, Cai Y, Geng L, Maeda Y, Nishimura S, Witzgall R, Ehrlich BE, Somlo S (2002) Polycystin-2 is an intracellular calcium release channel. Nat Cell Biol 4:191–197PubMedCrossRefGoogle Scholar
  59. 59.
    Anyatonwu GI, Ehrlich BE (2005) Organic cation permeation through the channel formed by polycystin-2. J Biol Chem 280:29488–29493PubMedCrossRefGoogle Scholar
  60. 60.
    Vassilev PM, Guo L, Chen XZ, Segal Y, Peng JB, Basora N, Babakhanlou H, Cruger G, Kanazirska M, Ye C, Brown EM, Hediger MA, Zhou J (2001) Polycystin-2 is a novel cation channel implicated in defective intracellular Ca2+ homeostasis in polycystic kidney disease. Biochem Biophys Res Commun 282:341–350PubMedCrossRefGoogle Scholar
  61. 61.
    Du J, Ding M, Sours-Brothers S, Graham S, Ma R (2008) Mediation of angiotensin II-induced Ca2+ signaling by polycystin 2 in glomerular mesangial cells. Am J Physiol Renal Physiol 294:F909–F918PubMedCrossRefGoogle Scholar
  62. 62.
    McGrath J, Somlo S, Makova S, Tian X, Brueckner M (2003) Two populations of node monocilia initiate left-right asymmetry in the mouse. Cell 114:61–73PubMedCrossRefGoogle Scholar
  63. 63.
    Nauli SM, Rossetti S, Kolb RJ, Alenghat FJ, Consugar MB, Harris PC, Ingber DE, Loghman-Adham M, Zhou J (2006) Loss of polycystin-1 in human cyst-lining epithelia leads to ciliary dysfunction. J Am Soc Nephrol 17:1015–1025PubMedCrossRefGoogle Scholar
  64. 64.
    Wang S, Zhang J, Nauli SM, Li X, Starremans PG, Luo Y, Roberts KA, Zhou J (2007) Fibrocystin/polyductin, found in the same protein complex with polycystin-2, regulates calcium responses in kidney epithelia. Mol Cell Biol 27:3241–3252PubMedCrossRefGoogle Scholar
  65. 65.
    Montalbetti N, Li Q, Gonzalez-Perrett S, Semprine J, Chen XZ, Cantiello HF (2005) Effect of hydro-osmotic pressure on polycystin-2 channel function in the human syncytiotrophoblast. Pflugers Arch 451:294–303PubMedCrossRefGoogle Scholar
  66. 66.
    Montalbetti N, Li Q, Timpanaro GA, Gonzalez-Perrett S, Dai XQ, Chen XZ, Cantiello HF (2005) Cytoskeletal regulation of calcium-permeable cation channels in the human syncytiotrophoblast: role of gelsolin. J Physiol 566:309–325PubMedCrossRefGoogle Scholar
  67. 67.
    Montalbetti N, Li Q, Wu Y, Chen XZ, Cantiello HF (2007) Polycystin-2 cation channel function in the human syncytiotrophoblast is regulated by microtubular structures. J Physiol 579:717–728PubMedCrossRefGoogle Scholar
  68. 68.
    Ma R, Li WP, Rundle D, Kong J, Akbarali HI, Tsiokas L (2005) PKD2 functions as an epidermal growth factor-activated plasma membrane channel. Mol Cell Biol 25:8285–8298PubMedCrossRefGoogle Scholar
  69. 69.
    Huang AL, Chen X, Hoon MA, Chandrashekar J, Guo W, Trankner D, Ryba NJ, Zuker CS (2006) The cells and logic for mammalian sour taste detection. Nature 442:934–938PubMedCrossRefGoogle Scholar
  70. 70.
    Davenport JR, Watts AJ, Roper VC, Croyle MJ, van Groen T, Wyss JM, Nagy TR, Kesterson RA, Yoder BK (2007) Disruption of intraflagellar transport in adult mice leads to obesity and slow-onset cystic kidney disease. Curr Biol 17:1586–1594PubMedCrossRefGoogle Scholar
  71. 71.
    Piontek K, Menezes LF, Garcia-Gonzalez MA, Huso DL, Germino GG (2007) A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1. Nat Med 13:1490–1495PubMedCrossRefGoogle Scholar
  72. 72.
    Dalagiorgou G, Basdra EK, Papavassiliou AG (2010) Polycystin-1: function as a mechanosensor. Int J Biochem Cell Biol 42:1610–1613PubMedCrossRefGoogle Scholar
  73. 73.
    Giamarchi A, Padilla F, Coste B, Raoux M, Crest M, Honore E, Delmas P (2006) The versatile nature of the calcium-permeable cation channel TRPP2. EMBO Rep 7:787–793PubMedCrossRefGoogle Scholar
  74. 74.
    Luo Y, Vassilev PM, Li X, Kawanabe Y, Zhou J (2003) Native polycystin-2 functions as a plasma membrane Ca2+-permeable cation channel in renal epithelia. Mol Cell Biol 23:2600–2607PubMedCrossRefGoogle Scholar
  75. 75.
    Cai Y, Tang Z (2010) Regulation of ciliary trafficking of polycystin-2 and the pathogenesis of autosomal dominant polycystic kidney disease. Zhong Nan Da Xue Xue Bao Yi Xue Ban 35:93–99PubMedGoogle Scholar
  76. 76.
    Hu J, Bae YK, Knobel KM, Barr MM (2006) Casein kinase II and calcineurin modulate TRPP function and ciliary localization. Mol Biol Cell 17:2200–2211PubMedCrossRefGoogle Scholar
  77. 77.
    Hidaka S, Konecke V, Osten L, Witzgall R (2004) PIGEA-14, a novel coiled-coil protein affecting the intracellular distribution of polycystin-2. J Biol Chem 279:35009–35016PubMedCrossRefGoogle Scholar
  78. 78.
    Streets AJ, Moon DJ, Kane ME, Obara T, Ong AC (2006) Identification of an N-terminal glycogen synthase kinase 3 phosphorylation site which regulates the functional localization of polycystin-2 in vivo and in vitro. Hum Mol Genet 15:1465–1473PubMedCrossRefGoogle Scholar
  79. 79.
    Geng L, Okuhara D, Yu Z, Tian X, Cai Y, Shibazaki S, Somlo S (2006) Polycystin-2 traffics to cilia independently of polycystin-1 by using an N-terminal RVxP motif. J Cell Sci 119:1383–1395PubMedCrossRefGoogle Scholar
  80. 80.
    Xu C, Rossetti S, Jiang L, Harris PC, Brown-Glaberman U, Wandinger-Ness A, Bacallao R, Alper SL (2007) Human ADPKD primary cyst epithelial cells with a novel, single codon deletion in the PKD1 gene exhibit defective ciliary polycystin localization and loss of flow-induced Ca2+ signaling. Am J Physiol Renal Physiol 292:F930–F945PubMedCrossRefGoogle Scholar
  81. 81.
    Somlo S, Ehrlich B (2001) Human disease: calcium signaling in polycystic kidney disease. Curr Biol 11:R356–R360PubMedCrossRefGoogle Scholar
  82. 82.
    Koulen P, Duncan RS, Liu J, Cohen NE, Yannazzo JA, McClung N, Lockhart CL, Branden M, Buechner M (2005) Polycystin-2 accelerates Ca2+ release from intracellular stores in Caenorhabditis elegans. Cell Calcium 37:593–601PubMedCrossRefGoogle Scholar
  83. 83.
    Cai Y, Anyatonwu G, Okuhara D, Lee KB, Yu Z, Onoe T, Mei CL, Qian Q, Geng L, Wiztgall R, Ehrlich BE, Somlo S (2004) Calcium dependence of polycystin-2 channel activity is modulated by phosphorylation at Ser812. J Biol Chem 279:19987–19995PubMedCrossRefGoogle Scholar
  84. 84.
    Sammels E, Parys JB, Missiaen L, De Smedt H, Bultynck G (2010) Intracellular Ca2+ storage in health and disease: a dynamic equilibrium. Cell Calcium 47:297–314PubMedCrossRefGoogle Scholar
  85. 85.
    Wegierski T, Steffl D, Kopp C, Tauber R, Buchholz B, Nitschke R, Kuehn EW, Walz G, Kottgen M (2009) TRPP2 channels regulate apoptosis through the Ca2+ concentration in the endoplasmic reticulum. EMBO J 28:490–499PubMedCrossRefGoogle Scholar
  86. 86.
    Geng L, Boehmerle W, Maeda Y, Okuhara DY, Tian X, Yu Z, Choe CU, Anyatonwu GI, Ehrlich BE, Somlo S (2008) Syntaxin 5 regulates the endoplasmic reticulum channel-release properties of polycystin-2. Proc Natl Acad Sci USA 105:15920–15925PubMedCrossRefGoogle Scholar
  87. 87.
    Xu GM, Gonzalez-Perrett S, Essafi M, Timpanaro GA, Montalbetti N, Arnaout MA, Cantiello HF (2003) Polycystin-1 activates and stabilizes the polycystin-2 channel. J Biol Chem 278:1457–1462PubMedCrossRefGoogle Scholar
  88. 88.
    Li Q, Montalbetti N, Shen PY, Dai XQ, Cheeseman CI, Karpinski E, Wu G, Cantiello HF, Chen XZ (2005) Alpha-actinin associates with polycystin-2 and regulates its channel activity. Hum Mol Genet 14:1587–1603PubMedCrossRefGoogle Scholar
  89. 89.
    Bai CX, Kim S, Li WP, Streets AJ, Ong AC, Tsiokas L (2008) Activation of TRPP2 through mDia1-dependent voltage gating. EMBO J 27:1345–1356PubMedCrossRefGoogle Scholar
  90. 90.
    Wu Y, Dai XQ, Li Q, Chen CX, Mai W, Hussain Z, Long W, Montalbetti N, Li G, Glynne R, Wang S, Cantiello HF, Wu G, Chen XZ (2006) Kinesin-2 mediates physical and functional interactions between polycystin-2 and fibrocystin. Hum Mol Genet 15:3280–3292PubMedCrossRefGoogle Scholar
  91. 91.
    Grimm DH, Cai Y, Chauvet V, Rajendran V, Zeltner R, Geng L, Avner ED, Sweeney W, Somlo S, Caplan MJ (2003) Polycystin-1 distribution is modulated by polycystin-2 expression in mammalian cells. J Biol Chem 278:36786–36793PubMedCrossRefGoogle Scholar
  92. 92.
    Hooper KM, Boletta A, Germino GG, Hu Q, Ziegelstein RC, Sutters M (2005) Expression of polycystin-1 enhances endoplasmic reticulum calcium uptake and decreases capacitative calcium entry in ATP-stimulated MDCK cells. Am J Physiol Renal Physiol 289:F521–F530PubMedCrossRefGoogle Scholar
  93. 93.
    Weber KH, Lee EK, Basavanna U, Lindley S, Ziegelstein RC, Germino GG, Sutters M (2008) Heterologous expression of polycystin-1 inhibits endoplasmic reticulum calcium leak in stably transfected MDCK cells. Am J Physiol Renal Physiol 294:F1279–F1286PubMedCrossRefGoogle Scholar
  94. 94.
    Wildman SS, Hooper KM, Turner CM, Sham JS, Lakatta EG, King BF, Unwin RJ, Sutters M (2003) The isolated polycystin-1 cytoplasmic COOH terminus prolongs ATP-stimulated Cl- conductance through increased Ca2+ entry. Am J Physiol Renal Physiol 285:F1168–F1178PubMedGoogle Scholar
  95. 95.
    Manzati E, Aguiari G, Banzi M, Manzati M, Selvatici R, Falzarano S, Maestri I, Pinton P, Rizzuto R, del Senno L (2005) The cytoplasmic C-terminus of polycystin-1 increases cell proliferation in kidney epithelial cells through serum-activated and Ca2+-dependent pathway(s). Exp Cell Res 304:391–406PubMedCrossRefGoogle Scholar
  96. 96.
    Santoso NG, Cebotaru L, Guggino WB (2011) Polycystin-1, 2, and STIM1 interact with IP3R to modulate ER Ca2+ release through the PI3 K/Akt pathway. Cell Physiol Biochem 27:715–726PubMedCrossRefGoogle Scholar
  97. 97.
    Decuypere JP, Monaco G, Kiviluoto S, Oh-hora M, Luyten T, De Smedt H, Parys JB, Missiaen L, Bultynck G (2010) STIM1, but not STIM2, is required for proper agonist-induced Ca2+ signaling. Cell Calcium 48:161–167PubMedCrossRefGoogle Scholar
  98. 98.
    Ahrabi AK, Terryn S, Valenti G, Caron N, Serradeil-Le Gal C, Raufaste D, Nielsen S, Horie S, Verbavatz JM, Devuyst O (2007) PKD1 haploinsufficiency causes a syndrome of inappropriate antidiuresis in mice. J Am Soc Nephrol 18:1740–1753PubMedCrossRefGoogle Scholar
  99. 99.
    Morel N, Vandenberg G, Ahrabi AK, Caron N, Desjardins F, Balligand JL, Horie S, Devuyst O (2009) PKD1 haploinsufficiency is associated with altered vascular reactivity and abnormal calcium signaling in the mouse aorta. Pflugers Arch 457:845–856PubMedCrossRefGoogle Scholar
  100. 100.
    Mekahli D, Sammels E, Luyten T, Welkenhuyzen K, van den Heuvel LP, Levtchenko EN, Gijsbers R, Bultynck G, Parys JB, De Smedt H, Missiaen L (2012) Polycystin-1 and polycystin-2 are both required to amplify inositol-trisphosphate-induced Ca2+ release. Cell Calcium 51:452–458PubMedCrossRefGoogle Scholar
  101. 101.
    Torres VE, Harris PC (2009) Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 76:149–168PubMedCrossRefGoogle Scholar
  102. 102.
    Belibi FA, Reif G, Wallace DP, Yamaguchi T, Olsen L, Li H, Helmkamp GM Jr, Grantham JJ (2004) Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int 66:964–973PubMedCrossRefGoogle Scholar
  103. 103.
    Hanaoka K, Devuyst O, Schwiebert EM, Wilson PD, Guggino WB (1996) A role for CFTR in human autosomal dominant polycystic kidney disease. Am J Physiol Cell Physiol 270:C389–C399Google Scholar
  104. 104.
    Gattone VH 2nd, Wang X, Harris PC, Torres VE (2003) Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9:1323–1326PubMedCrossRefGoogle Scholar
  105. 105.
    Antoni FA (2012) Interactions between intracellular free Ca2+ and cyclic AMP in neuroendocrine cells. Cell Calcium 51:260–266PubMedCrossRefGoogle Scholar
  106. 106.
    Choi YH, Suzuki A, Hajarnis S, Ma Z, Chapin HC, Caplan MJ, Pontoglio M, Somlo S, Igarashi P (2011) Polycystin-2 and phosphodiesterase 4C are components of a ciliary A-kinase anchoring protein complex that is disrupted in cystic kidney diseases. Proc Natl Acad Sci USA 108:10679–10684PubMedCrossRefGoogle Scholar
  107. 107.
    Gresh L, Fischer E, Reimann A, Tanguy M, Garbay S, Shao X, Hiesberger T, Fiette L, Igarashi P, Yaniv M, Pontoglio M (2004) A transcriptional network in polycystic kidney disease. EMBO J 23:1657–1668PubMedCrossRefGoogle Scholar
  108. 108.
    Wang X, Harris PC, Somlo S, Batlle D, Torres VE (2009) Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease. Nephrol Dial Transplant 24:526–534PubMedCrossRefGoogle Scholar
  109. 109.
    Lefkimmiatis K, Srikanthan M, Maiellaro I, Moyer MP, Curci S, Hofer AM (2009) Store-operated cyclic AMP signalling mediated by STIM1. Nat Cell Biol 11:433–442PubMedCrossRefGoogle Scholar
  110. 110.
    Spirli C, Locatelli L, Fiorotto R, Morell CM, Fabris L, Pozzan T, Strazzabosco M (2012) Altered store operated calcium entry increases cyclic 3′,5′-adenosine monophosphate production and extracellular signal-regulated kinases 1 and 2 phosphorylation in polycystin-2-defective cholangiocytes. Hepatology 55:856–868PubMedCrossRefGoogle Scholar
  111. 111.
    Yamaguchi T, Pelling JC, Ramaswamy NT, Eppler JW, Wallace DP, Nagao S, Rome LA, Sullivan LP, Grantham JJ (2000) cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int 57:1460–1471PubMedCrossRefGoogle Scholar
  112. 112.
    Yamaguchi T, Nagao S, Wallace DP, Belibi FA, Cowley BD, Pelling JC, Grantham JJ (2003) Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int 63:1983–1994PubMedCrossRefGoogle Scholar
  113. 113.
    Cowley BD Jr (2008) Calcium, cyclic AMP, and MAP kinases: dysregulation in polycystic kidney disease. Kidney Int 73:251–253PubMedCrossRefGoogle Scholar
  114. 114.
    Yamaguchi T, Wallace DP, Magenheimer BS, Hempson SJ, Grantham JJ, Calvet JP (2004) Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem 279:40419–40430PubMedCrossRefGoogle Scholar
  115. 115.
    Yamaguchi T, Hempson SJ, Reif GA, Hedge AM, Wallace DP (2006) Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells. J Am Soc Nephrol 17:178–187PubMedCrossRefGoogle Scholar
  116. 116.
    Nagao S, Nishii K, Yoshihara D, Kurahashi H, Nagaoka K, Yamashita T, Takahashi H, Yamaguchi T, Calvet JP, Wallace DP (2008) Calcium channel inhibition accelerates polycystic kidney disease progression in the Cy/+rat. Kidney Int 73:269–277PubMedCrossRefGoogle Scholar
  117. 117.
    Aguiari G, Trimi V, Bogo M, Mangolini A, Szabadkai G, Pinton P, Witzgall R, Harris PC, Borea PA, Rizzuto R, del Senno L (2008) Novel role for polycystin-1 in modulating cell proliferation through calcium oscillations in kidney cells. Cell Prolif 41:554–573PubMedCrossRefGoogle Scholar
  118. 118.
    Puri S, Magenheimer BS, Maser RL, Ryan EM, Zien CA, Walker DD, Wallace DP, Hempson SJ, Calvet JP (2004) Polycystin-1 activates the calcineurin/NFAT (nuclear factor of activated T-cells) signaling pathway. J Biol Chem 279:55455–55464PubMedCrossRefGoogle Scholar
  119. 119.
    Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, Flask CA, Novick AC, Goldfarb DA, Kramer-Zucker A, Walz G, Piontek KB, Germino GG, Weimbs T (2006) The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 103:5466–5471PubMedCrossRefGoogle Scholar
  120. 120.
    Lieberthal W, Levine JS (2012) Mammalian target of rapamycin and the kidney part I: the signaling pathway. Am J Physiol Renal Physiol 303:F1–F10PubMedCrossRefGoogle Scholar
  121. 121.
    Lieberthal W, Levine JS (2012) Mammalian target of rapamycin and the kidney part II: pathophysiology and therapeutic implications. Am J Physiol Renal Physiol 303:F180–F191PubMedCrossRefGoogle Scholar
  122. 122.
    Boletta A (2009) Emerging evidence of a link between the polycystins and the mTOR pathways. Pathogenetics 2:6PubMedCrossRefGoogle Scholar
  123. 123.
    Lieberthal W, Levine JS (2009) The role of the mammalian target of rapamycin (mTOR) in renal disease. J Am Soc Nephrol 20:2493–2502PubMedCrossRefGoogle Scholar
  124. 124.
    Distefano G, Boca M, Rowe I, Wodarczyk C, Ma L, Piontek KB, Germino GG, Pandolfi PP, Boletta A (2009) Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6 K and 4EBP1. Mol Cell Biol 29:2359–2371PubMedCrossRefGoogle Scholar
  125. 125.
    Shibazaki S, Yu Z, Nishio S, Tian X, Thomson RB, Mitobe M, Louvi A, Velazquez H, Ishibe S, Cantley LG, Igarashi P, Somlo S (2008) Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1. Hum Mol Genet 17:1505–1516PubMedCrossRefGoogle Scholar
  126. 126.
    Ballif BA, Roux PP, Gerber SA, MacKeigan JP, Blenis J, Gygi SP (2005) Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. Proc Natl Acad Sci USA 102:667–672PubMedCrossRefGoogle Scholar
  127. 127.
    Boehlke C, Kotsis F, Patel V, Braeg S, Voelker H, Bredt S, Beyer T, Janusch H, Hamann C, Godel M, Muller K, Herbst M, Hornung M, Doerken M, Kottgen M, Nitschke R, Igarashi P, Walz G, Kuehn EW (2010) Primary cilia regulate mTORC1 activity and cell size through Lkb1. Nat Cell Biol 12:1115–1122PubMedCrossRefGoogle Scholar
  128. 128.
    Hoyer-Hansen M, Bastholm L, Szyniarowski P, Campanella M, Szabadkai G, Farkas T, Bianchi K, Fehrenbacher N, Elling F, Rizzuto R, Mathiasen IS, Jaattela M (2007) Control of macroautophagy by calcium, calmodulin-dependent kinase kinase-beta, and Bcl-2. Mol Cell 25:193–205PubMedCrossRefGoogle Scholar
  129. 129.
    Takiar V, Nishio S, Seo-Mayer P, King JD Jr, Li H, Zhang L, Karihaloo A, Hallows KR, Somlo S, Caplan MJ (2011) Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci USA 108:2462–2467PubMedCrossRefGoogle Scholar
  130. 130.
    Kim E, Arnould T, Sellin LK, Benzing T, Fan MJ, Gruning W, Sokol SY, Drummond I, Walz G (1999) The polycystic kidney disease 1 gene product modulates Wnt signaling. J Biol Chem 274:4947–4953PubMedCrossRefGoogle Scholar
  131. 131.
    Habas R, Dawid IB (2005) Dishevelled and Wnt signaling: is the nucleus the final frontier? J Biol 4:2PubMedCrossRefGoogle Scholar
  132. 132.
    Simons M, Gloy J, Ganner A, Bullerkotte A, Bashkurov M, Kronig C, Schermer B, Benzing T, Cabello OA, Jenny A, Mlodzik M, Polok B, Driever W, Obara T, Walz G (2005) Inversin, the gene product mutated in nephronophthisis type II, functions as a molecular switch between Wnt signaling pathways. Nat Genet 37:537–543PubMedCrossRefGoogle Scholar
  133. 133.
    Saadi-Kheddouci S, Berrebi D, Romagnolo B, Cluzeaud F, Peuchmaur M, Kahn A, Vandewalle A, Perret C (2001) Early development of polycystic kidney disease in transgenic mice expressing an activated mutant of the beta-catenin gene. Oncogene 20:5972–5981PubMedCrossRefGoogle Scholar
  134. 134.
    Lal M, Song X, Pluznick JL, Di Giovanni V, Merrick DM, Rosenblum ND, Chauvet V, Gottardi CJ, Pei Y, Caplan MJ (2008) Polycystin-1 C-terminal tail associates with beta-catenin and inhibits canonical Wnt signaling. Hum Mol Genet 17:3105–3117PubMedCrossRefGoogle Scholar
  135. 135.
    Happe H, Leonhard WN, van der Wal A, van de Water B, Lantinga-van Leeuwen IS, Breuning MH, de Heer E, Peters DJ (2009) Toxic tubular injury in kidneys from Pkd1-deletion mice accelerates cystogenesis accompanied by dysregulated planar cell polarity and canonical Wnt signaling pathways. Hum Mol Genet 18:2532–2542PubMedCrossRefGoogle Scholar
  136. 136.
    Romaker D, Puetz M, Teschner S, Donauer J, Geyer M, Gerke P, Rumberger B, Dworniczak B, Pennekamp P, Buchholz B, Neumann HP, Kumar R, Gloy J, Eckardt KU, Walz G (2009) Increased expression of secreted frizzled-related protein 4 in polycystic kidneys. J Am Soc Nephrol 20:48–56PubMedCrossRefGoogle Scholar
  137. 137.
    Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, Bennett C, Harada Y, Stankunas K, Wang CY, He X, MacDougald OA, You M, Williams BO, Guan KL (2006) TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126:955–968PubMedCrossRefGoogle Scholar
  138. 138.
    Boca M, D’Amato L, Distefano G, Polishchuk RS, Germino GG, Boletta A (2007) Polycystin-1 induces cell migration by regulating phosphatidylinositol 3-kinase-dependent cytoskeletal rearrangements and GSK3beta-dependent cell–cell mechanical adhesion. Mol Biol Cell 18:4050–4061PubMedCrossRefGoogle Scholar
  139. 139.
    Woo D (1995) Apoptosis and loss of renal tissue in polycystic kidney diseases. N Engl J Med 333:18–25PubMedCrossRefGoogle Scholar
  140. 140.
    Lanoix J, D’Agati V, Szabolcs M, Trudel M (1996) Dysregulation of cellular proliferation and apoptosis mediates human autosomal dominant polycystic kidney disease (ADPKD). Oncogene 13:1153–1160PubMedGoogle Scholar
  141. 141.
    Zhou XJ, Kukes G (1998) Pathogenesis of autosomal dominant polycystic kidney disease: role of apoptosis. Diagn Mol Pathol 7:65–68PubMedCrossRefGoogle Scholar
  142. 142.
    Wilson PD (2004) Polycystic kidney disease. N Engl J Med 350:151–164PubMedCrossRefGoogle Scholar
  143. 143.
    Ecder T, Melnikov VY, Stanley M, Korular D, Lucia MS, Schrier RW, Edelstein CL (2002) Caspases, Bcl-2 proteins and apoptosis in autosomal-dominant polycystic kidney disease. Kidney Int 61:1220–1230PubMedCrossRefGoogle Scholar
  144. 144.
    Edelstein CL (2005) What is the role of tubular epithelial cell apoptosis in polycystic kidney disease (PKD)? Cell Cycle 4:1550–1554PubMedCrossRefGoogle Scholar
  145. 145.
    Goilav B, Satlin LM, Wilson PD (2008) Pathways of apoptosis in human autosomal recessive and autosomal dominant polycystic kidney diseases. Pediatr Nephrol 23:1473–1482PubMedCrossRefGoogle Scholar
  146. 146.
    Bhunia AK, Piontek K, Boletta A, Liu L, Qian F, Xu PN, Germino FJ, Germino GG (2002) PKD1 induces p21(waf1) and regulation of the cell cycle via direct activation of the JAK-STAT signaling pathway in a process requiring PKD2. Cell 109:157–168PubMedCrossRefGoogle Scholar
  147. 147.
    Park JY, Schutzer WE, Lindsley JN, Bagby SP, Oyama TT, Anderson S, Weiss RH (2007) p21 is decreased in polycystic kidney disease and leads to increased epithelial cell cycle progression: roscovitine augments p21 levels. BMC Nephrol 8:12PubMedCrossRefGoogle Scholar
  148. 148.
    Bukanov NO, Smith LA, Klinger KW, Ledbetter SR, Ibraghimov-Beskrovnaya O (2006) Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature 444:949–952PubMedCrossRefGoogle Scholar
  149. 149.
    Park JY, Park SH, Weiss RH (2009) Disparate effects of roscovitine on renal tubular epithelial cell apoptosis and senescence: implications for autosomal dominant polycystic kidney disease. Am J Nephrol 29:509–515PubMedCrossRefGoogle Scholar
  150. 150.
    Trudel M, D’Agati V (1992) A model of polycystic kidney disease in SBM transgenic mice. Contrib Nephrol 97:47–59PubMedGoogle Scholar
  151. 151.
    Trudel M, Lanoix J, Barisoni L, Blouin MJ, Desforges M, L’Italien C, D’Agati V (1997) C-myc-induced apoptosis in polycystic kidney disease is Bcl-2 and p53 independent. J Exp Med 186:1873–1884PubMedCrossRefGoogle Scholar
  152. 152.
    Schafer K, Gretz N, Bader M, Oberbaumer I, Eckardt KU, Kriz W, Bachmann S (1994) Characterization of the Han: SPRD rat model for hereditary polycystic kidney disease. Kidney Int 46:134–152PubMedCrossRefGoogle Scholar
  153. 153.
    Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ (1993) Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 75:229–240PubMedCrossRefGoogle Scholar
  154. 154.
    Sorenson CM, Padanilam BJ, Hammerman MR (1996) Abnormal postpartum renal development and cystogenesis in the bcl-2−/− mouse. Am J Physiol 271:F184–F193PubMedGoogle Scholar
  155. 155.
    Bouillet P, Robati M, Bath M, Strasser A (2005) Polycystic kidney disease prevented by transgenic RNA interference. Cell Death Differ 12:831–833PubMedCrossRefGoogle Scholar
  156. 156.
    Hughes P, Robati M, Lu W, Zhou J, Strasser A, Bouillet P (2006) Loss of PKD1 and loss of Bcl-2 elicit polycystic kidney disease through distinct mechanisms. Cell Death Differ 13:1123–1127PubMedCrossRefGoogle Scholar
  157. 157.
    Moser M, Pscherer A, Roth C, Becker J, Mucher G, Zerres K, Dixkens C, Weis J, Guay-Woodford L, Buettner R, Fassler R (1997) Enhanced apoptotic cell death of renal epithelial cells in mice lacking transcription factor AP-2beta. Genes Dev 11:1938–1948PubMedCrossRefGoogle Scholar
  158. 158.
    Tao Y, Kim J, Faubel S, Wu JC, Falk SA, Schrier RW, Edelstein CL (2005) Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease. Proc Natl Acad Sci USA 102:6954–6959PubMedCrossRefGoogle Scholar
  159. 159.
    Tao Y, Kim J, Stanley M, He Z, Faubel S, Schrier RW, Edelstein CL (2005) Pathways of caspase-mediated apoptosis in autosomal-dominant polycystic kidney disease (ADPKD). Kidney Int 67:909–919PubMedCrossRefGoogle Scholar
  160. 160.
    Edelstein CL (2008) Mammalian target of rapamycin and caspase inhibitors in polycystic kidney disease. Clin J Am Soc Nephrol 3:1219–1226PubMedCrossRefGoogle Scholar
  161. 161.
    Tao Y, Zafar I, Kim J, Schrier RW, Edelstein CL (2008) Caspase-3 gene deletion prolongs survival in polycystic kidney disease. J Am Soc Nephrol 19:749–755PubMedCrossRefGoogle Scholar
  162. 162.
    Trudel M, Barisoni L, Lanoix J, D’Agati V (1998) Polycystic kidney disease in SBM transgenic mice: role of c-myc in disease induction and progression. Am J Pathol 152:219–229PubMedGoogle Scholar
  163. 163.
    Trudel M, D’Agati V, Costantini F (1991) C-myc as an inducer of polycystic kidney disease in transgenic mice. Kidney Int 39:665–671PubMedCrossRefGoogle Scholar
  164. 164.
    Ricker JL, Mata JE, Iversen PL, Gattone VH (2002) c-myc antisense oligonucleotide treatment ameliorates murine ARPKD. Kidney Int 61:S125–S131PubMedCrossRefGoogle Scholar
  165. 165.
    Goilav B (2011) Apoptosis in polycystic kidney disease. Biochim Biophys Acta 1812:1272–1280PubMedCrossRefGoogle Scholar
  166. 166.
    Boca M, Distefano G, Qian F, Bhunia AK, Germino GG, Boletta A (2006) Polycystin-1 induces resistance to apoptosis through the phosphatidylinositol 3-kinase/Akt signaling pathway. J Am Soc Nephrol 17:637–647PubMedCrossRefGoogle Scholar
  167. 167.
    Park EY, Sung YH, Yang MH, Noh JY, Park SY, Lee TY, Yook YJ, Yoo KH, Roh KJ, Kim I, Hwang YH, Oh GT, Seong JK, Ahn C, Lee HW, Park JH (2009) Cyst formation in kidney via B-Raf signaling in the PKD2 transgenic mice. J Biol Chem 284:7214–7222PubMedCrossRefGoogle Scholar
  168. 168.
    Kip SN, Hunter LW, Ren Q, Harris PC, Somlo S, Torres VE, Sieck GC, Qian Q (2005) [Ca2+]i reduction increases cellular proliferation and apoptosis in vascular smooth muscle cells: relevance to the ADPKD phenotype. Circ Res 96:873–880PubMedCrossRefGoogle Scholar
  169. 169.
    Szado T, Vanderheyden V, Parys JB, De Smedt H, Rietdorf K, Kotelevets L, Chastre E, Khan F, Landegren U, Soderberg O, Bootman MD, Roderick HL (2008) Phosphorylation of inositol 1,4,5-trisphosphate receptors by protein kinase B/Akt inhibits Ca2+ release and apoptosis. Proc Natl Acad Sci USA 105:2427–2432PubMedCrossRefGoogle Scholar
  170. 170.
    Decuypere JP, Monaco G, Bultynck G, Missiaen L, De Smedt H, Parys JB (2011) The IP3 receptor-mitochondria connection in apoptosis and autophagy. Biochim Biophys Acta 1813:1003–1013PubMedCrossRefGoogle Scholar
  171. 171.
    Zheng R, Zhang Z, Lv X, Fan J, Chen Y, Wang Y, Tan R, Liu Y, Zhou Q (2008) Polycystin-1 induced apoptosis and cell cycle arrest in G0/G1 phase in cancer cells. Cell Biol Int 32:427–435PubMedCrossRefGoogle Scholar
  172. 172.
    Winyard PJ, Nauta J, Lirenman DS, Hardman P, Sams VR, Risdon RA, Woolf AS (1996) Deregulation of cell survival in cystic and dysplastic renal development. Kidney Int 49:135–146PubMedCrossRefGoogle Scholar

Copyright information

© The Author(s) 2012

Authors and Affiliations

  • D. Mekahli
    • 1
  • Jan B. Parys
    • 1
  • G. Bultynck
    • 1
  • L. Missiaen
    • 1
  • H. De Smedt
    • 1
  1. 1.Laboratory of Molecular and Cellular Signaling, Department of Cellular and Molecular MedicineKU LeuvenLeuvenBelgium

Personalised recommendations